Cerevel Therapeutics Holdings, Inc. (CERE)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cerevel Therapeutics Holdings, Inc. (“Cerevel” or “the Company”) (NASDAQ: CERE). Investors who purchased Cerevel securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether Cerevel has violated federal securities laws. 

Investigation Details: 

On August 2, 2023, Cerevel issued a press release reporting its second quarter 2023 financial results and business updates.  Among other items, Cerevel announced its decision to delay key data readouts until “mid-year 2024.”  On this news, Cerevel’s stock price fell $4.32 per share, or 14.09%, to close at $26.33 per share on August 2, 2023.  Then, on August 3, 2023, Bank of America downgraded Cerevel, citing the delayed data readouts.  On this news, Cerevel’s stock price fell sharply during intraday trading on August 3, 2023. 

What’s Next? 

If you are aware of any facts relating to this investigation or purchased Cerevel securities, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.  

Why Bronstein, Gewirtz & Grossman: 

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.  Our firm has recovered hundreds of millions of dollars for investors nationwide.  

Attorney advertising. Prior results do not guarantee similar outcomes.


Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | [email protected]